

design presented in this notice reflects only changes suggested by external peer

reviewers and further discussion among research team members.

FDA estimates the burden of this collection of information as follows:

TABLE 4—ESTIMATED ANNUAL REPORTING BURDEN ¹

Activity	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Screener	19,120	1	19,120	0.03 (2 min.)	637
Pretest	900	1	900	0.33 (20 min.)	300
Main Study	8,660	1	8,660	0.33 (20 min.)	2,887
Total					3,824

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

IV. References

The following references have been placed on display in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday. (FDA has verified the Web site addresses, but FDA is not responsible for any subsequent changes to the Web sites after this document publishes in the **Federal Register**.)

1. Agency for Healthcare Research and Quality (AHRQ), AHRQ Home Page, "Fact Sheets on Recovery Act Investments in Comparative Effectiveness Research" (<http://www.ahrq.gov/fund/cerfactsheets/>). Last accessed May 23, 2011.
2. Ang, S.H. and S.B. Leong, "Comparative Advertising: Superiority Despite Interference?" *Asia Pacific Journal of Management*, vol. 11, pp. 33–46, 1994.
3. Demirdjian, Z.S., "Sales Effectiveness of Comparative Advertising: An Experimental Field Investigation," *Journal of Consumer Research*, vol. 10, pp. 362–364, 1983.
4. Grewal, D., S. Kavanoor, E.F. Fern, et al., "Comparative Versus Noncomparative Advertising: A Meta-Analysis," *Journal of Marketing*, vol. 61, pp. 1–15, 1997.
5. Priester, J.R., J. Godek, D.J. Nayakankuppum, et al., "Brand Congruity and Comparative Advertising: When and Why Comparative Advertisements Lead to Greater Elaboration," *Journal of Consumer Psychology*, vol. 14, pp. 115–123, 2004.
6. Rogers, J.C. and T.G. Williams, "Comparative Advertising Effectiveness: Practitioners' Perceptions Versus Academic Research Findings," *Journal of Advertising Research*, vol. 29, pp. 22–37, 1989.
7. Miniard, P.W., M.J. Barone, R.L. Rose, et al., "A Re-Examination of the Relative Persuasiveness of Comparative and Noncomparative Advertising," *Advances in Consumer Research*, vol. 21, pp. 299–303, 1994.
8. Droge, C. and R.Y. Darmon, "Associative

Positioning Strategies Through Comparative Advertising: Attribute Versus Overall Similarity Approaches," *Journal of Marketing Research*, vol. 24, pp. 377–388, 1987.

9. Gorn, G.J. and C.B. Weinberg, "The Impact of Comparative Advertising on Perception and Attitude: Some Positive Findings," *Journal of Consumer Research*, vol. 11, pp. 719–727, 1984.
10. Iyer, E.S., "The Influence of Verbal Content and Relative Newness on the Effectiveness of Comparative Advertising," *Journal of Advertising*, vol. 17, pp. 15–21, 1988.
11. Schwartz, L.M., S. Woloshin, and H.G. Welch, "Using a Drug Facts Box to Communicate Drug Benefits and Harms: Two Randomized Trials," *Annals of Internal Medicine*, vol. 150, pp. 516–527, 2009.
12. Hauber, A.B., A.F. Mohamed, F.R. Johnson, et al., "Treatment Preferences and Medication Adherence of People With Type 2 Diabetes Using Oral Glucose-Lowering Agents," *Diabetic Medicine: A Journal of the British Diabetic Association*, vol. 26, pp. 416–424, 2009.
13. Mitra, A., J. Swasy, and K. Aikin, "How Do Consumers Interpret Market Leadership Claims in Direct-to-Consumer Advertising of Prescription Drugs?" *Advances in Consumer Research*, vol. 33, pp. 381–387, 2006.

Dated: December 5, 2011.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2011–31609 Filed 12–8–11; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2011-N-0769]

Notice of Listing of Members of the Food and Drug Administration's Senior Executive Service Performance Review Board

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a list of members who may be named to serve on FDA's Senior Executive Performance Review Board or Panels, which oversee the evaluation of performance appraisals of FDA's Senior Executive Service (SES) members. The Civil Service Reform Act of 1978 requires that the appointment of Performance Review Board Members be published in the **Federal Register**.

FOR FURTHER INFORMATION CONTACT: Mary Wathen, Office of Management Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, rm. 4310, Silver Spring, MD 20993, (301) 796–8848.

SUPPLEMENTARY INFORMATION: The Civil Service Reform Act of 1978 (5 U.S.C. 4314(c)(4)) (Public Law 95–454) requires that the appointment of Performance Review Board Members be published in the **Federal Register**. The following persons may be named to serve on FDA's Performance Review Board or Panels.

SES	Non-SES
Jeanne Anson Deborah Autor Jane Axelrad Lawrence Bachorik Glenda Barfell	Dennis Baker Norman Baylor Nega Beru Gail Costello Lawrence Deyton

SES	Non-SES
Catherine Beck	Bernadette Dunham
Susan Bernard	Ted Elkin
Malcolm Bertoni	Jeff Farrar
Eric Blumberg	William Flynn
Beverly Chernaik	Christy Foreman
Dara Corrigan	Malcolm Frazier
Kathleen Crosby	Alberto Gutierrez
L'Tonya Davis	Sheryl Lard-Whiteford
David Elder	Murray Lumpkin
Denise Esposito	William Maisel
Tracy Forfa	Karen Midthun
Lillian Gill	Ellen Morrison
Deborah Henderson	Steven Musser
Kimberly Holden	Steven Pollack
Jeanne Ireland	Jonathan Sackner-Bernstein
Melanie Keller	Barbara Schneeman
Michael Landa	Rachel Sherman
Caroline Lewis	Jeffrey Shuren
Eric Lindblom	Ann Simoneau
Mary Anne Marlarkey	William Slikker
Diane Maloney	Steven Solomon
Daniel McChesney	Stephen Spielberg
William McConagha	Roberta Wagner
Patrick McGarey	David White
Ruth McKee	Carolyn Wilson
Alfred R. Miller	Janet Woodcock
Theresa Mullin	Robert Yetter
Deanna Murphy	Donald Zink
Melinda Plaisier	
Lynne Rice	
Mark Roh	
James Sigg	
Steven Silverman	
Howard Sklamberg	
Philip Spiller	
Nancy Stade	
John Taylor	
Michael Taylor	
Brian Trent	
Mary Lou Valdez	
Steven Vaughn	
Stephen Veneruso	
Helen Winkle	
Ann Wion	

Dated: December 1, 2011.

Margaret A. Hamburg,

Commissioner of Food and Drugs.

[FR Doc. 2011-31579 Filed 12-8-11; 8:45 am]

BILLING CODE 4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, NCI SPORE in Prostate and Gastrointestinal Cancers.

Date: February 15-16, 2012.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Caron A Lyman, PhD, Scientific Review Officer, National Cancer Institute, NIH, Division of Extramural Activities, Research Programs Review Branch, 6116 Executive Blvd., Room 8119, Bethesda, MD 20892-8328, (301) 451-4761, lymanca@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, International Tobacco and Health Research and Capacity Building Program.

Date: February 28-29, 2012.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

Contact Person: Gerald G. Lovinger, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8055A, Bethesda, MD 20892-8329, (301) 496-7987, lovingeg@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Small Grants Program for Cancer Epidemiology.

Date: March 22-23, 2012.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Jeffrey E. DeClue, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8059, Bethesda, MD 20892-8329, (301) 496-7904, decluej@mail.nih.gov.

Name of Committee: National Cancer Institute Special Emphasis Panel, Nanotechnology Reformulations for Cancer Drugs.

Date: April 12, 2012.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate contract proposals.

Place: Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

Contact Person: Jeffrey E. DeClue, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8059, Bethesda, MD 20892-8329, (301) 496-7904, decluej@mail.nih.gov.

Information is also available on the Institute's/Center's home page: <http://deainfo.nci.nih.gov/advisory/sep/sep.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: December 5, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011-31679 Filed 12-8-11; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

[Docket No. DHS-2011-0115]

Request for Public Comments Concerning U.S.-Canada Action Plan for Perimeter Security and Economic Competitiveness

AGENCY: Office of Policy, DHS.

ACTION: Notice.

SUMMARY: The United States and Canada are staunch allies, vital economic partners, neighbors, and steadfast friends. We share common values, communities, and deep links among our citizens. The extensive mobility of people, goods, capital, and information between our two countries has helped ensure that our societies remain open, democratic, prosperous, and secure.

On February 4, 2011, President Barack Obama and Canadian Prime Minister Stephen Harper announced *Beyond the Border: A Shared Vision for Perimeter Security and Economic Competitiveness*. This declaration describes a perimeter approach to security in which the United States and Canada share responsibility for the security and resilience of our nations.